We Are Committed To Transforming The Lives Of Patients With Neurological And Rare Diseases. Welcome to Longboard Pharmaceuticals.
Location: United States, California, San Diego
Employees: 11-50
Founded date: 2020
Investors 1
| Date | Name | Website |
| - | HBM Partne... | hbmpartner... |
Mentions in press and media 11
| Date | Title | Description |
| 13.10.2025 | Lundbeck’s bexicaserin receives Breakthrough Therapy Designation in China for the treatment of seizures in severe rare epilepsies | Lundbeck’s bexicaserin receives Breakthrough Therapy Designation in China for the treatment of seizures in severe rare epilepsies Mon, Oct 13, 2025 08:00 CET Report this content Accelerated pathway underscores urgent need for innovative sol... |
| 20.02.2025 | The Rise of Healthcare Marketing: A New Era of Innovation and Strategy | The healthcare marketing landscape is evolving. Agencies are no longer just service providers; they are strategic partners in the healthcare ecosystem. Two recent developments highlight this shift: Moon Rabbit's impressive growth and Strate... |
| 19.02.2025 | Moon Rabbit Wraps 2024 with Key Executive Hires, New NYC Headquarters, Major Client Wins | Healthcare agency also won Fierce Pharma's 'Best New Brand Launch' award, opened London office, instituted workplace enhancements for expanding team NEW YORK, Feb. 19, 2025 /PRNewswire-PRWeb/ -- Moon Rabbit, an independent advertising and m... |
| 05.02.2025 | Lundbeck reached record revenue of DKK 22 billion in 2024 with accelerated growth for strategic brands (+21% CER) | Lundbeck reached record revenue of DKK 22 billion in 2024 with accelerated growth for strategic brands (+21% CER) Wed, Feb 05, 2025 07:23 CET Report this content Key highlights Lundbeck’s total revenue grew by +14% CER[1] (+11% DKK) to DKK ... |
| 30.01.2025 | Lundbeck announces positive results from 12-month Open-Label Extension (OLE) of the PACIFIC trial evaluating bexicaserin in participants with Developmental and Epileptic Encephalopathies | Lundbeck announces positive results from 12-month Open-Label Extension (OLE) of the PACIFIC trial evaluating bexicaserin in participants with Developmental and Epileptic Encephalopathies Thu, Jan 30, 2025 09:00 CET Report this content Bexic... |
| 28.11.2024 | Lundbeck announces expiration of Longboard tender offer and that all tender offer conditions are fulfilled | Lundbeck announces expiration of Longboard tender offer and that all tender offer conditions are fulfilled Thu, Nov 28, 2024 07:56 CET Report this content A significant step forward in Lundbeck’s Focused Innovator strategy and advancing the... |
| 13.11.2024 | Accelerated growth for strategic brands (+21% CER) drives revenue up 13% CER in the first nine months of 2024 | Accelerated growth for strategic brands (+21% CER) drives revenue up 13% CER in the first nine months of 2024 Wed, Nov 13, 2024 07:29 CET Report this content Accelerated growth for strategic brands (+21% CER) drives revenue up 13% CER in th... |
| 17.10.2024 | Lundbeck makes huge bid for Longboard | Lundbeck makes huge bid for Longboard Thu, Oct 17, 2024 08:45 CET Report this content Danish Lundbeck has made a bid for American Longboard Pharmaceuticals worth USD 2.6 billion. With this deal, they would get access to Bexicaserin, a promi... |
| 15.10.2024 | Access Bank's Sustainable Finance Accelerator: A Green Light for Nigeria's Future | In a world grappling with climate change, Access Bank Plc has taken a bold step. The bank recently launched its Sustainable Finance Accelerator Program, a beacon of hope for eco-friendly initiatives in Nigeria. This program aims to empower ... |
| 15.10.2024 | Датская компания Lundbeck приобретает американского разработчика лекарства от эпилепсии за $2,6 млрд | Сделка расширяет портфель услуг копенгагенской компании Lundbeck по лечению неврологических заболеваний, таких как болезнь Паркинсона, мигрень и болезнь Альцгеймера. Lundbeck прогнозирует потенциальный мировой пик продаж в размере $1,5–2 мл... |
Show more